FDA recall record

Actavis Pharmaceuticals buPROPion Hydrochloride Extended - Release Tablets (XL) 300 mg, 30 recall — FDA D-175-2013

Failed Dissolution Specifications; 8-hours for the 18-month stability testing point.

Class IIIclassification
D-175-2013official record ID
Mar 6, 2013report date

Recall record at a glance

Official recordD-175-2013
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmActavis Pharmaceuticals
Report dateMar 6, 2013
Recall initiation dateJan 4, 2013
Quantity14,856 bottles
LocationMorristown, NJ, United States

Official product description

buPROPion Hydrochloride Extended - Release Tablets (XL) 300 mg, 30 tablet bottles, Rx Only, NDC 67767-142-30 Actavis Distributed by: Actavis South Atlantic LLC Sunrise, FL 33325 Packaged by by: America Health Packaging Columbus, OH 43217

Why the product was recalled

Failed Dissolution Specifications; 8-hours for the 18-month stability testing point.

Distribution information

Nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.